Senior Dutch researcher sacked for manipulating data in rheumatoid arthritis drug trial
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5267 (Published 23 August 2013) Cite this as: BMJ 2013;347:f5267- Tony Sheldon
- 1Utrecht
A senior researcher in rheumatology at a leading Dutch university hospital has been sacked after admitting manipulating data in a clinical trial for the past three years.
The Leiden University Medical Center has consequently halted the TIGER trial for which the researcher was responsible, a phase II patient study investigating the use of the drug omalizumab to treat rheumatoid arthritis (Anti-IgE therapy (omalizumab) in IgE-ACPA positive RA).
Publications based on fraudulent data, which appeared in the US Proceedings of the National Academy of Sciences (PNAS) in 2010 and the Annals of the Rheumatic Diseases in 2011 are in the process of being withdrawn. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.